• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

15
15
15
15
4

COUNTRY

15

CATEGORIES

  • 11
  • 7
  • 4
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

9
10
23
31

PUBLISHED

0
7
11
31

PRODUCT TYPE

25
6

Search "China Company Research - Jiangsu Hengrui Medicine Co., Ltd " returned 31 results.

Jiangsu Hengrui Medicine Co., Ltd. (600276) - Financial and Strategic SWOT Analysis Review

Jiangsu Hengrui Medicine Co., Ltd. (600276) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has...

May 2015
FROM

Investigation Report on China's Raloxifene Market, 2010-2019

According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50%...

June 2015
FROM

Investigation Report on China's Raloxifene Market, 2010-2019

According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50%...

June 2015
FROM

Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019

Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti-cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999,...

June 2015
FROM

Research Report on Top 50 Companies of China's Pharmaceutical Industry, 2011-2012

" Since 2006, the proportion of China pharmaceutical industry output in GDP has remained stable In the past five years, the proportion fell slightly in 2007, while in other years it kept a growth trend...

November 2011
FROM

Investigation Report on China Tropisetron Market, 2010-2019

Cancer patients are afraid of such adverse reactions as nausea and emesis caused by chemotherapy. Severe nausea and vomiting will make future chemotherapy a daunting experience for patients. They may...

June 2015
FROM

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014

With the mushroom growth of world diagnostic imaging equipments and apparatuses, as for X-CT contrast media, iodinated contrast media serving as the main one is witnessing unprecedented development...

January 2014
FROM

Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2014

With the mushroom growth of world diagnostic imaging equipments and apparatuses, as for X-CT contrast media, iodinated contrast media serving as the main one is witnessing unprecedented development...

January 2014
FROM

Research Report on Top 100 Enterprises in Chinese Pharmaceutical Industry, 2009-2010

In 2008, the sales of Chinese pharmaceutical industry amounted to RMB 677 776 billion, rising by over 20% YOY Among the sub-industries, the sales growth rate of the biological product industry was 31...

December 2009
FROM

Research Report on Chinese Chemical Pharmaceutical Industry 2010-2011

In China, the chemical pharmaceutical industry includes the chemical API industry and the chemical preparation industry The chemical active pharmaceutical ingredients (API) manufacture refers to the...

October 2010
FROM

Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019

Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti- cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999,...

December 1899
FROM

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal...

March 2014
FROM

Anesthetic Effect - Pipeline Review, H1 2015

‘Anesthetic Effect - Pipeline Review, H1 2015’, provides an overview of the Anesthetic Effect’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development...

April 2015
FROM

Throat Cancer Global Clinical Trials Review, H2, 2013

Throat Cancer Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Throat Cancer Global Clinical Trials Review, H2, 2013" provides data on the Throat Cancer clinical trial scenario....

November 2013
FROM

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014 Summary This, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014’, provides an overview of the Chemotherapy Induced Neutropenia’s...

November 2014
FROM

Investigation Report on China Tropisetron Market, 2010-2019

Cancer patients are afraid of such adverse reactions as nausea and emesis caused by chemotherapy. Severe nausea and vomiting will make future chemotherapy a daunting experience for patients. They may...

December 1899
FROM

China Resources Sanjiu Medical & Pharmaceutical Co Ltd

A textual analysis of the financial results for China Resources Sanjiu Medical & Pharmaceutical Co Ltd compared to selected competitors. Also included are quantitative analyses of the company's financial...

June 2015
FROM

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999) - Financial and Strategic SWOT Analysis Review

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations....

June 2013
FROM

Company Study of Jiangsu Hengrui Medicine Co, Ltd., 2007

Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the companys profit. In the...

June 2007
FROM

Company Study of Jiangsu Hengrui Medicine Co, Ltd. 2007

Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the companys profit. In the...

June 2007
FROM
Loading Indicator

Our Clients

Credit Suisse Group Heinz Company Telenor Group Deutsche Bank AG Solvay S.A. APC by Schneider Electric Lindt & Sprüngli AG